Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study
Titel:
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study
Auteur:
Fu, Weijun Bang, Soo-Mee Huang, Honghui Kim, Kihyun Li, Wei An, Gang Lee, Je-Jung Cai, Zhen Jin, Jie Wang, Yafei Chim, Chor Sang Carson, Robin Liu, Rui Zhao, Man Chen, Xi Cui, Canchan Hou, Jian Wang, Jianxiang